Prasugrel Benefits Patients With Diabetes and Multivessel Disease Post-PCI: TUXEDO-2 Trial
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Prasugrel Benefits Patients With Diabetes and Multivessel Disease Post-PCI: TUXEDO-2 Trial
-
Narrated by:
-
By:
The findings from the TUXEDO‑2 trial provide important clinical insights for managing high‑risk patients with diabetes and multivessel coronary disease undergoing stenting. By directly comparing ticagrelor and prasugrel within a dual antiplatelet therapy regimen, the trial helps clarify whether one agent offers superior protection in this complex population. These results may influence clinical decision‑making, particularly if meaningful differences in outcomes are demonstrated.
In this interview, Sidney C. Smith Jr., MD, MACC and Sripal Bangalore, MD, MHA discuss the TUXEDO-2 Trial.
No reviews yet